Gerald R. Cooper Laboratory Safety Award

The Gerald R. Cooper Laboratory Safety Award recognizes exceptional contributions that promote enhanced safety in the laboratory setting.

Lab safetyDuring his 53 years at CDC, Dr. Gerald Cooper was not only an outstanding CDC scientist, often called the “Father of Cholesterol,” but also an enthusiastic supporter of a strong safety program for both laboratory and non-laboratory staff. He recognized when safety concerns needed to be addressed and was a determined advocate for taking corrective action as soon as a safety problem surfaced. He served as chair of CDC’s Occupational Health and Safety Committee and was always engaged in laboratory safety issues.

When Dr. Cooper passed away in May 2009 at age 94, he was still challenging CDC to promote and implement safety programs, especially for the Division of Laboratory Science. Several groups recognized the important contributions Dr. Cooper had made to CDC’s laboratory safety activates and sought to promote a Gerald R. Cooper Laboratory Safety Award in his honor.

The award was established in 2010 with a generous gift from Battelle to create an endowed fund at the CDC Foundation. Each year, the Gerald R. Cooper Laboratory Safety Award is presented to a CDC employee who has made outstanding contributions to laboratory safety at the annual CDC and ATSDR Honor Awards program.

531
Lab safety
Gerald R. Cooper Laboratory Safety Award
United States of America
To recognize exceptional contributions that promote enhanced safety in the laboratory setting.
Established by Batelle with support from The Columbus Foundation
CDC’s Office of the Director

Laboratory Surveillance for Factor XIII Deficiency

763
chronic
Laboratory Surveillance for Factor XIII Deficiency
United States of America
To provide support for Factor XIII testing to accurately diagnose patients in the United States in order to enhance the surveillance of rare bleeding disorders.
Novo Nordisk Inc.
CDC’s National Center on Birth Defects and Developmental Disabilities

A Visit to CDC's Insectary

Read more

Hormone Laboratory Collaborations

524
Lab
Hormone Laboratory Collaborations
United States of America
To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.
AB SCIEX; Abbott Laboratories; American University of Beirut; Ann & Robert H. Lurie Children's Hospital of Chicago; ARUP Laboratories; Beckman Coulter, Inc.; Bio-Rad Laboratories, Inc.; BMH Holdings (TMS BioScience Labs); Covance; DiaSorin Inc.; DIAsource Immunoassays; Douglass Hanly Moir Pathology; Endoceutics, Inc.; Euroimmun Medizinische Labordiagnostika AG; Fujirebio Diagnostics, Inc; Fujirebio Inc.; Health Canada; Immunodiagnostic Systems Inc.; Immunotech S.A.S. (Beckman Coulter, Inc); Laboratory Corporation of America Holdings; Los Angeles Biomedical Research Institute; Microgenics Corporation (Thermo Fisher Scientific, Inc.); New England Research Institutes, Inc.; Harvard University (Partners HealthCare System, Inc.); Pathology Associates Medical Laboratories; Quest Diagnostics; Reprosource Fertility Diagnostics; Roche Diagnostics Corporation; Sahlgrenska University Hospital; Siemens; Social & Scientific Systems, Inc.; Tosoh Bioscience, Inc.; Tricore Reference Laboratories; University College Cork; University of Helsinki; VU University Medical Center Amsterdam; ZRT Laboratory; multiple donors
CDC's Division of Laboratory Sciences

Newborn Screening Translation Research Initiative

newborn screeningFor new parents the world over, the birth of a healthy child is a joy they remember throughout their lives. For some, however, that joy is tempered by serious health problems that arise from disorders like phenylketonuria, sickle cell disease or hypothyroidism. Fortunately for thousands of babies born in the United States each year, those treatable diseases are caught and diagnosed within days of birth, thanks in large part to the work of the newborn screening laboratory program at the Centers for Disease Control and Prevention.

“Newborn screening is the most successful lab-based prevention program in public health,” says Dr. Robert Vogt, principal investigator of the Newborn Screening Translation Research Initiative (NSTRI).

Virtually all babies born in the United States are tested for an array of treatable, but potentially deadly, conditions within 48 hours of birth. Blood samples collected by a simple “heel stick” are sent to one of more than 70 newborn screening labs across the country for analysis. Testing in these labs is routinely evaluated by CDC’s Newborn Screening and Molecular Biology Branch, which operates the only comprehensive program in the world for assuring the quality of newborn screening tests. The reach of the CDC program also extends to over 450 labs in more than 60 countries.

Currently, early detection by laboratory tests helps prevent death and disability from dozens of disorders. Early identification of these disorders gives babies a healthy start and dramatically reduces health care costs associated with treatment of lifelong debilitating conditions.

For the future, the CDC research group is working to identify new tests to add to the mix. Dr. Vogt boils down the research conducted by his program into a simple summary saying, “The purpose of this group is to anticipate screening tests that are not now being conducted.”

The CDC Program was instrumental in expanding the recommended panel of newborn screening tests to include Severe Combined Immune Deficiency (SCID), known more commonly as the Boy in the Bubble Syndrome. The screen is now being piloted at labs in Wisconsin and Massachusetts, and thus far more than 200,000 babies have been screened for the syndrome. The first newborn with SCID was identified just this year. The screening test should soon become routine throughout the United States, adding yet another layer of protection for newborns.

Gathered with his research colleagues near their lab at CDC, Dr. Vogt is quick to recognize the role of the CDC Foundation. “We now have five major areas of investigation that are supported in one way or another by the CDC Foundation,” he says. “In some cases it is direct funding support and in other cases there are partnerships that are in-kind. We use the CDC Foundation to ‘do more, faster.’ That motto really applies.”

by David Snyder

328/ 779
Newborn screening
Newborn Screening Translation Research Initiative
United States of America
To improve four major areas of newborn screening: 1) developing new screening methods for specific diseases, 2) integrating state public health laboratories in the translation process through collaborative field studies, 3) expanding the global reach of newborn screening, and 4) adapting innovative technologies for screening and quality assurance.
Genzyme Corporation; Biogen
CDC’s National Center for Environmental Health; California Department of Health Services; Emory University; Jeffrey Modell Foundation; Kennedy Krieger Institute; Medical College of Georgia; New York State Department of Health; The Johns Hopkins Bloomberg School of Public Health; The University of Texas at San Antonio; University of Washington; Washington State Department of Health; Wisconsin State Laboratory of Hygiene; Association of Public Health Laboratories; Illinois Department of Public Health; Georgia Public Health Laboratory; University of California San Francisco; New England Newborn Screening Program; University of Pittsburgh Medical Center Mayo Clinic; University of Pittsburgh School of Medicine; National Taiwan University Hospital
Subscribe to Laboratory Research and Analysis